It is approved by the Food and Drug Administration in the United States for use in chronic myelogenous leukemia and Philadelphia chromosome‐positive acute lymphoblastic leukemia based on its ability to block BCR‐ABL (a mutation that is formed by the fusion of two genes, known as BCR and ABL) and other proteins. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.